Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Oct 22, 2024
Product Development
Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy
BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Jun 18, 2024
Data Byte
FDA label expansions in May: Two new indications for BMS’s CAR T
Plus: Lilly’s RET inhibitor receives accelerated approval for younger patients
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Jan 31, 2024
Product Development
Clinical roundup: Data for Vertex, Sarepta, Lilly, Alligator, Corbus and Vera
Vertex’s analgesic heads for submission; plus the latest from Sarepta in DMD, Lilly in hearing loss, and more
BioCentury | Dec 13, 2023
Data Byte
November follow-ons: Xenon raises more than one third of month’s total
Eight biopharmas brought in a combined $949M in follow-on financing; nearly all had gained value by the end of the month
BioCentury | Apr 28, 2023
Deals
April 28 Quick Takes: Quest Diagnostics buys Haystack
Plus: Zai takes global rights to MediLink’s ADC and updates from ImmunoGen and Amgen
Items per page:
1 - 10 of 305